Sinopharm Group 15on Stock Price To Sales
| X2S1 Stock | EUR 13.10 0.20 1.55% |
SINOPHARM GROUP 15ON fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Stock. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP stock.
SINOPHARM |
SINOPHARM GROUP 15ON Company Price To Sales Analysis
SINOPHARM GROUP's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, SINOPHARM GROUP 15ON has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Distribution industry. The price to sales for all Germany stocks is 100.0% higher than that of the company.
SINOPHARM Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.SINOPHARM GROUP is currently under evaluation in price to sales category among its peers.
SINOPHARM Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Shares Outstanding | 624.13 M | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 7.03 X | |||
| Revenue | 546.15 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 23.5 B | |||
| Net Income | 7.87 B | |||
| Cash And Equivalents | 34.36 B | |||
| Cash Per Share | 55.05 X | |||
| Total Debt | 86.79 B | |||
| Debt To Equity | 0.93 % | |||
| Current Ratio | 1.29 X | |||
| Book Value Per Share | 105.05 X | |||
| Earnings Per Share | 1.77 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.76 | |||
| Market Capitalization | 7.05 B | |||
| Annual Yield | 0.05 % | |||
| Last Dividend Paid | 0.75 |
About SINOPHARM GROUP Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP 15ON's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP 15ON based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in SINOPHARM Stock
SINOPHARM GROUP financial ratios help investors to determine whether SINOPHARM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SINOPHARM with respect to the benefits of owning SINOPHARM GROUP security.